Alaunos Therapeutics Regains Compliance With Nasdaq Stockholders' Equity Requirement

PUBT · 1d ago
Alaunos Therapeutics Regains Compliance With Nasdaq Stockholders' Equity Requirement
  • Nasdaq confirmed on October 22, 2026, that Alaunos Therapeutics regained compliance with its $2.5 million minimum stockholders' equity requirement.
  • The delisting matter is closed. The common stock will continue trading on The Nasdaq Capital Market.
  • Compliance followed completion of a private placement financing on October 14, 2026.
  • The Nasdaq Hearings Panel hearing scheduled for November 10, 2026, was canceled.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-430507), on October 23, 2026, and is solely responsible for the information contained therein.